Roche Wins FDA Nod For Tecentriq Combination In Adjuvant Stage III DMMR Colon Cancer As 36-Month Disease-Free Survival Reaches 86% Versus 76% With Chemotherapy Alone In ATOMIC Trial

Roche has received FDA approval for Tecentriq in combination with chemotherapy for adjuvant stage III dMMR colon cancer, based on results from the ATOMIC trial which demonstrated an 86% disease-free survival rate at 36 months compared to 76% with chemotherapy alone. This marks the first approved adjuvant immunotherapy regimen for this cancer type, establishing Tecentriq as a new standard of care post-surgery. The approval is Roche's twelfth indication for Tecentriq in the US.